Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Typical course for receptor positive early breast cancer

SABCS 2009

9 - 13 Sep 2009

Published: 9 Feb 2010

Views: 8901

Rating:

Save

Dr Kimberly Blackwell - Duke University Medical Centre, USA

The typical presentation and course of receptor positive early breast cancer. The significance of positive receptors, whether oestrogen, progesterone or Her2neu. The comparative advantages of tamoxifen and the latest aromatase. Ongoing trials which are open to recruitment. Recent evidence for changes in personalised management of hormone sensitive early breast cancer.

Watch Dr Blackwell presenting her results at the official SABCS press conference here.

Related Videos

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer

Dr Sitna Mwanzi - Kenyatta National Hospital, Nairobi, Kenya

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer ( Dr Sitna Mwanzi - Kenyatta National Hospital, Nairobi, Kenya )

Preoperative endocrine therapy in premenopausal women leads to sparing...

Dr Oleg Gluz - Krankenhaus Bethesda, Mönchengladbach, Germany

Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients ( Dr Oleg Gluz - Krankenhaus Bethesda, Mönchengladbach, Germany )

OncoAlert Round Up for August 25th - 31st, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

CDK4/6 inhibitors added to first line show no greater benefit when compared to...

Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands

CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC ( Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands )

Prognostic value of HER2-low status in breast cancer: A systematic review and...

Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis ( Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy )

PHERGain trial ID's early breast cancer cases that benefit from dual HER2...

Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo ( Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain )

ASCO 2023: Breast cancer research highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ASCO 2023: Breast cancer research highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Adding ribociclib to endocrine therapy shows an improvement in invasive disease...

Prof Dennis Slamon - UCLA, Los Angeles, USA

Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients ( Prof Dennis Slamon - UCLA, Los Angeles, USA )

More from ecancer